Table 4.
Infused alloreactive T cell dose and clinical outcome (n = 11)
| Patient ID | Disease | HTLp (1/x) before SD | HTLp (1/x) after SD | SD CD3+ dose, × 108/kg | HTLp dose/kg* | aGVHD†grade | aGVHD type | aGVHD treatment‡ | Survival status | COD | Survival days | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | NHL | 217 547 | 128 378 | 1.4 | 1091 | 2 | Gut only | High dose | D | NRM | 227 | Steroid-responsive gut and liver GVHD, died 8 months after transplantation of a myocardial infarction |
| 13 | RAEB | 141 844 | 206 625 | 0.7 | 339 | 4 | Gut, liver | High dose | D | NRM | 67 | Steroid refractory GVHD |
| 4 | RAEB-T | 166 082 | 603 994 | 0.7 | 248 | 0 | NR | NR | A | NR | 642 | Alive in CR |
| 16 | AML ref | 316 636 | 605 261 | 1.2 | 198 | 1 | Skin only | Low dose | A | 164 | Relapse day +95, developed grade III gut GVHD after abruptly stopping CSA for relapse | |
| 10 | AML ref | 122 560 | 563 013 | 1.1 | 195 | 0 | NR | NR | D | Relapse | 164 | Relapse day +100, developed extensive cGVHD following unmanipulated DLI |
| 5 | sAML (CR1) | 119 332 | 518 786 | 1.5 | 135 | 2 | Skin only | Low dose | A | NR | 550 | Alive in CR |
| 3 | RAEB | 398 085 | 1 219 886 | 1.4 | 115 | 2 | Skin only | Low dose | A | NR | 792 | Alive in CR |
| 8 | AML ref | 110 306 | 918 713 | 1.0 | 109 | 0 | NR | NR | D | Relapse | 208 | Relapse death (day +208) |
| 7 | tMDS | 69 978 | 737 977 | 0.5 | 68 | 1 | Skin only | Low dose | D | Relapse | 136 | Relapse death (day +136) |
| 9 | sAML (CR1) | 171 883 | 383 470 | 0.2 | 52 | 0 | NR | NR | A | NR | 317 | Alive in CR |
| 15 | sAML (CR1) | 163 945 | 1 850 089 | 0.9 | 49 | 0 | NR | NR | A | NR | 177 | Alive in CR |
HTLp indicates helper T-lymphocyte precursor; SD, selective depletion; aGVHD, acute graft-versus-host disease; COD, cause of death; D, dead; NRM, nonrelapse mortality; RAEB, refractory anemia and excess of blasts; RAEB-T, RAEB transformed; A, alive; CR, complete remission; ref, refractory; CSA, cyclosporine; cGVHD, chronic graft versus host disease; sAML, secondary AML (arising from MDS); tMDS, therapy-related MDS; and NR, not relevant.
HTLp dose/kg determined by product of CD3 dose in SD allograft per kilogram recipient weight and the frequency of alloreactive HTLp (1/x) after SD
GVHD before day +100
Low-dose treatment defined by oral steroid dose equal to 0.5 mg/kg, high-dose therapy defined by oral steroid use of more than 0.5 mg/kg or need for intravenous steroids